AU2002331064B2 - Peptidomimetics of biologically active metallopeptides - Google Patents
Peptidomimetics of biologically active metallopeptides Download PDFInfo
- Publication number
- AU2002331064B2 AU2002331064B2 AU2002331064A AU2002331064A AU2002331064B2 AU 2002331064 B2 AU2002331064 B2 AU 2002331064B2 AU 2002331064 A AU2002331064 A AU 2002331064A AU 2002331064 A AU2002331064 A AU 2002331064A AU 2002331064 B2 AU2002331064 B2 AU 2002331064B2
- Authority
- AU
- Australia
- Prior art keywords
- phe
- compound
- following
- determined
- msh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31140401P | 2001-08-10 | 2001-08-10 | |
US60/311,404 | 2001-08-10 | ||
PCT/US2002/025574 WO2003013571A1 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002331064A1 AU2002331064A1 (en) | 2003-06-19 |
AU2002331064B2 true AU2002331064B2 (en) | 2007-08-23 |
Family
ID=23206723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002331064A Ceased AU2002331064B2 (en) | 2001-08-10 | 2002-08-12 | Peptidomimetics of biologically active metallopeptides |
Country Status (6)
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
CN1638790A (zh) * | 2002-01-29 | 2005-07-13 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
WO2005102340A1 (en) * | 2003-05-30 | 2005-11-03 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
WO2005079574A1 (en) * | 2004-01-21 | 2005-09-01 | Palatin Technologies, Inc. | Bicyclic melanocorin-specific compounds |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
BRPI0607379B8 (pt) | 2005-01-26 | 2021-05-25 | Allergan Inc | composição farmacêutica de efeito analgésico |
US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
CN102690221B (zh) | 2005-12-23 | 2014-12-03 | 西兰岛药物有限公司 | 改性的拟赖氨酸化合物 |
CA2651762A1 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
MX2009001043A (es) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso. |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
PT2104535E (pt) * | 2007-01-10 | 2011-03-31 | Irm Llc | Compostos e composições como inibidores da protease de activação de canal |
WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
MX2009011069A (es) | 2007-04-13 | 2009-12-03 | Univ Michigan | Mimeticos de smac diazo biciclicos y usos de los mismos. |
US20090081197A1 (en) * | 2007-06-01 | 2009-03-26 | Palatin Technologies, Inc. | Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity |
US20090076029A1 (en) * | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
ES2439964T3 (es) | 2008-02-29 | 2014-01-27 | Mimetica Pty Limited | Antagonistas del receptor 5 de melanocortina, de 1,4-diazepan-2-onas 3-sustituidas |
US8008291B2 (en) * | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
AU2009246397B2 (en) | 2008-05-13 | 2013-01-17 | University Of Kansas | Metal abstraction peptide (MAP) tag and associated methods |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
AU2009314200B2 (en) | 2008-11-17 | 2011-11-17 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
BR112012011787B1 (pt) * | 2009-11-23 | 2022-03-03 | Palatin Technologies, Inc | Peptídeo cíclico e composição farmacêutica |
AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
EP2635570B1 (en) | 2010-11-01 | 2017-12-13 | RFS Pharma, LLC. | Novel specific hcv ns3 protease inhibitors |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
MX339762B (es) * | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2802574A4 (en) | 2012-01-12 | 2015-06-24 | Rfs Pharma Llc | INHIBITORS OF HCV NS3 PROTEASE |
US9187735B2 (en) | 2012-06-01 | 2015-11-17 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
GB201521903D0 (en) | 2015-12-11 | 2016-01-27 | Electrophoretics Ltd | Isorbaric mass labels |
EP3618847B1 (en) | 2017-05-05 | 2021-04-07 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
CN110981936B (zh) * | 2018-09-28 | 2021-10-12 | 北京京东方技术开发有限公司 | 类肽化合物及其制备方法、寡聚物、药物组合物和试剂盒 |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148923A (en) | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US4626549A (en) | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
IT1157365B (it) | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
US4711957A (en) | 1979-07-13 | 1987-12-08 | The B. F. Goodrich Company | Synthesis of 2-keto-1,4-diazacycloalkanes |
US4434454A (en) * | 1981-02-06 | 1984-02-28 | Day J Michael | Active lighting system including light control keyboard |
US4766125A (en) | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
US4968684A (en) | 1987-04-01 | 1990-11-06 | Janssen Pharmaceutica N.V. | Method of improving sleep |
PT90619B (pt) | 1988-05-23 | 1994-10-31 | Glaxo Group Ltd | Processo para a preparacao de compostos de piperazina |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4997836A (en) | 1988-11-11 | 1991-03-05 | Takeda Chemical Industries, Ltd. | Trisubstituted piperazine compounds, their production and use |
US5120713A (en) | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
WO1992020661A1 (en) | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
SE9202266D0 (sv) | 1992-07-31 | 1992-07-31 | Kabi Pharmacia Ab | Novel piperazine carboxamides |
US5432691A (en) * | 1992-11-18 | 1995-07-11 | Vari-Lite, Inc. | Automated truss module with deployment mechanism |
US5344830A (en) | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
DK0690843T3 (da) | 1993-03-25 | 2000-11-13 | Upjohn Co | Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet |
HUT70045A (en) | 1993-06-17 | 1995-09-28 | Takeda Chemical Industries Ltd | 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them |
WO1995000497A1 (en) | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
US5599809A (en) | 1994-09-29 | 1997-02-04 | Merck & Co., Inc. | Method for improving reproductive efficiency in farm animals |
US6245764B1 (en) | 1995-03-24 | 2001-06-12 | Molecumetics Ltd. | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins |
US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU700693B2 (en) | 1995-04-13 | 1999-01-14 | Aventis Pharmaceuticals Inc. | Novel substituted piperazine derivatives having tachykinin receptor antagonists activity |
DE69620165T2 (de) | 1995-04-26 | 2002-10-31 | Takeda Chemical Industries Ltd | Piperazinone als inhibitoren von blutplattchenaggregation |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
WO1996038471A1 (en) | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
DE19518988A1 (de) | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
US5891418A (en) | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
US6184223B1 (en) | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
ATE219064T1 (de) | 1995-12-18 | 2002-06-15 | Fujisawa Pharmaceutical Co | Piperazinderivative als tachykinin antagonisten |
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6303611B1 (en) | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5880128A (en) | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
GB9611461D0 (en) * | 1996-06-01 | 1996-08-07 | Ciba Geigy Ag | New compounds |
US6331285B1 (en) | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
AU724098B2 (en) | 1996-06-12 | 2000-09-14 | Kyowa Hakko Kogyo Co. Ltd. | Lipid metabolism improving agent |
US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
JP4024309B2 (ja) * | 1996-10-22 | 2007-12-19 | 第一三共株式会社 | 新規な感染症治療薬 |
US5734054A (en) | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US5965565A (en) | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
KR20000057595A (ko) | 1996-12-17 | 2000-09-25 | 후지야마 아키라 | Mmp 또는 tnf의 억제제로서 피페라진 화합물 |
DE69735384T2 (de) | 1996-12-20 | 2006-08-10 | Alza Corp., Mountain View | Gelzusammensetzungen und verfahren |
AU735760B2 (en) | 1997-04-24 | 2001-07-12 | Merck Sharp & Dohme Limited | Use of a NK-1 receptor antagonist and an SSRI for treating obesity |
SI0986413T1 (en) | 1997-05-27 | 2004-12-31 | Direct-Haler A/S | Inhaler for powdered medicaments |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US5968938A (en) | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
US6287587B2 (en) | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
US6211626B1 (en) | 1997-08-26 | 2001-04-03 | Color Kinetics, Incorporated | Illumination components |
US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
US5892038A (en) | 1997-12-08 | 1999-04-06 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
US6613234B2 (en) * | 1998-04-06 | 2003-09-02 | Ciphergen Biosystems, Inc. | Large pore volume composite mineral oxide beads, their preparation and their applications for adsorption and chromatography |
US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6284735B1 (en) | 1998-04-28 | 2001-09-04 | Lion Bioscience Ag | HP-3228 and related peptides to treat sexual dysfunction |
AU3768799A (en) * | 1998-04-28 | 1999-11-16 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
PL194839B1 (pl) | 1998-04-29 | 2007-07-31 | Ortho Mcneil Pharm Inc | Nowa N-podstawiona aminotetralina, kompozycja farmaceutyczna zawierająca ją i zastosowanie jej w leczeniu otyłości i innych zaburzeń |
CA2329881C (en) | 1998-05-11 | 2010-03-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
JP2002517444A (ja) * | 1998-06-11 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としてのスピロピペリジン誘導体 |
CA2334315C (en) * | 1998-06-30 | 2011-07-26 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
FR2780649B1 (fr) | 1998-07-06 | 2001-03-09 | Univ Paris Vii Denis Diderot | Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine |
WO2000005373A2 (en) | 1998-07-21 | 2000-02-03 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity |
WO2000009492A1 (en) | 1998-08-12 | 2000-02-24 | Pfizer Products Inc. | Tace inhibitors |
MXPA01002798A (es) * | 1998-09-17 | 2003-06-06 | Chu Sainte Justine | Antagonistas del receptor acoplado a la proteina g. |
GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
US6800636B2 (en) | 1998-12-18 | 2004-10-05 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6372747B1 (en) | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6432959B1 (en) | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
US6294539B1 (en) | 1999-01-19 | 2001-09-25 | Advanced Syntech, Llc | Heterocyclic hydroxamic acid derivatives as MMP inhibitors |
AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
DE60045216D1 (de) | 1999-03-03 | 2010-12-23 | Optinose As | Nasales Verabreichungsgerät |
US6033656A (en) | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
WO2003006620A2 (en) | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
WO2001005401A1 (en) | 1999-07-16 | 2001-01-25 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
WO2001013112A1 (en) * | 1999-08-12 | 2001-02-22 | Palatin Technologies, Inc. | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
US6294525B1 (en) | 1999-09-01 | 2001-09-25 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
EP1214409B1 (en) | 1999-09-08 | 2006-05-17 | Genentech, Inc. | Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
GB9921239D0 (en) | 1999-09-08 | 1999-11-10 | Plant Bioscience Ltd | Plant resistance gene |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
CA2388417A1 (en) | 1999-09-22 | 2001-03-29 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US6515122B1 (en) | 1999-09-24 | 2003-02-04 | Lion Bioscience Ag | Tetracyclic benzimidazole derivatives and combinatorial libraries thereof |
US6458789B1 (en) | 1999-09-29 | 2002-10-01 | Lion Bioscience Ag | 2-aminopyridine derivatives and combinatorial libraries thereof |
CA2386750A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
WO2001030808A1 (en) * | 1999-10-27 | 2001-05-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor-ligand binding |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
JP2001184828A (ja) * | 1999-12-21 | 2001-07-06 | Sony Corp | ライナ貼付方法及びライナ貼付装置 |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6462046B2 (en) | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
CA2396307A1 (en) * | 2000-01-18 | 2001-07-26 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
EP1125579A3 (en) | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
EP1254114A2 (en) | 2000-01-28 | 2002-11-06 | Melacure Therapeutics AB | Melanocortin receptor agonists and antagonists |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
WO2001070347A1 (en) | 2000-03-17 | 2001-09-27 | Fit Express, Inc. | Golf swing conditioner |
EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
US6458790B2 (en) | 2000-03-23 | 2002-10-01 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
CA2403631A1 (en) | 2000-03-23 | 2001-09-27 | Brenda L. Palucki | Spiropiperidine derivatives as melanocortin receptor agonists |
CN1450999A (zh) | 2000-03-31 | 2003-10-22 | 辉瑞产品公司 | 新的哌嗪衍生物 |
EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | MELANOCORTIN RECEPTOR AGONISTS |
IL153706A0 (en) | 2000-06-27 | 2003-07-06 | Taisho Pharmaceutical Co Ltd | Therapeutic preparation of anxiety neurosis or depression, and piperazine derivatives |
BR0111567A (pt) | 2000-06-28 | 2003-05-06 | Pfizer Prod Inc | Ligandos do receptor de melanocortina |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US20020032238A1 (en) | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
PT1315750E (pt) | 2000-08-30 | 2007-05-31 | Hoffmann La Roche | Péptidos cíclicos com actividade agonista para o receptor 4 de melanocortina |
US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
KR100394083B1 (ko) | 2000-12-04 | 2003-08-06 | 학교법인 성신학원 | 도파민 d3 및 d4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법 |
US6612805B2 (en) | 2000-12-05 | 2003-09-02 | Emu Unterwasserpumpen Gmbh | Hydrodynamic machine |
JP2004522720A (ja) | 2000-12-15 | 2004-07-29 | ファイザー・インク | 雄性性的機能障害の処置 |
WO2002059117A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
AU2002238106A1 (en) | 2001-02-13 | 2002-08-28 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
AU2002255597B8 (en) | 2001-02-28 | 2006-10-26 | Merck Sharp & Dohme Corp. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2002067869A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
EP1236723A1 (en) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
HUP0600103A2 (en) | 2001-03-02 | 2006-06-28 | Bristol Myers Squibb Co | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
JP2005511475A (ja) | 2001-03-02 | 2005-04-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物 |
US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
GB0107751D0 (en) | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
EP1385823B1 (en) | 2001-04-09 | 2006-12-13 | Chiron Corporation | Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists |
US6911447B2 (en) * | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
MXPA03010232A (es) | 2001-05-11 | 2004-03-16 | Biovitrum Ab | Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central. |
WO2002092566A1 (fr) | 2001-05-15 | 2002-11-21 | Taisho Pharmaceutical Co.,Ltd. | Derives d'arginine |
CN100356917C (zh) | 2001-05-15 | 2007-12-26 | 霍夫曼-拉罗奇有限公司 | 用作糖尿病治疗中的PPAR-α和PPAR-γ激活剂的羧酸取代的噁唑衍生物 |
US6593362B2 (en) | 2001-05-21 | 2003-07-15 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
CA2447865C (en) | 2001-06-20 | 2010-07-20 | Pfizer Products Inc. | Novel sulfonic acid derivatives |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
AR036674A1 (es) | 2001-08-28 | 2004-09-29 | Schering Corp | Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos |
AU2002326948A1 (en) | 2001-09-18 | 2003-04-01 | Bristol-Myers Squibb Company | Piperizinones as modulators of chemokine receptor activity |
US20050069883A1 (en) | 2001-09-26 | 2005-03-31 | Howard Andrew D. | Melanin-concentrating hormone receptor antagonist binding protein |
EP1465867A1 (en) | 2001-10-09 | 2004-10-13 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
EA006243B1 (ru) | 2001-10-22 | 2005-10-27 | Пфайзер Продактс Инк. | Производные пиперазина с антагонистической активностью к рецептору ccr1 |
SG176310A1 (en) | 2001-11-08 | 2011-12-29 | Ortho Mcneil Pharm Inc | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
AU2002367087A1 (en) | 2001-12-21 | 2003-07-15 | 7Tm Pharma A/S | Method for the treatment of mc receptor related disorders with a chelate and/or a chelator |
WO2003053927A1 (fr) | 2001-12-21 | 2003-07-03 | Taisho Pharmaceutical Co.,Ltd. | Dérivé de piperazine |
CA2473036A1 (en) | 2002-01-23 | 2003-07-31 | Paul Leslie Ornstein | Melanocortin receptor agonists |
US20030207814A1 (en) | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
US20030195187A1 (en) | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
EP1487474A4 (en) | 2002-02-25 | 2006-11-29 | Chiron Corp | INTRANASAL ADMINISTRATION OF MC4-R AGONISTS |
AU2003230367A1 (en) | 2002-05-10 | 2003-11-11 | Neurocrine Biosciences, Inc. | Substituted piperazine as melanocortin receptors ligands |
AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
TW200609219A (en) | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
US20090076029A1 (en) | 2007-06-01 | 2009-03-19 | Palatin Technologies, Inc. | Compounds and Methods for Treating Obesity |
-
2002
- 2002-08-12 CA CA002462200A patent/CA2462200A1/en not_active Abandoned
- 2002-08-12 JP JP2003518577A patent/JP2005504043A/ja active Pending
- 2002-08-12 WO PCT/US2002/025574 patent/WO2003013571A1/en active Application Filing
- 2002-08-12 EP EP02768507A patent/EP1425029A4/en not_active Withdrawn
- 2002-08-12 AU AU2002331064A patent/AU2002331064B2/en not_active Ceased
-
2004
- 2004-01-21 US US10/761,889 patent/US7326707B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,419 patent/US7807678B2/en not_active Expired - Fee Related
- 2004-02-10 US US10/776,657 patent/US7189755B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,932 patent/US7601753B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7807678B2 (en) | 2010-10-05 |
US20040171520A1 (en) | 2004-09-02 |
EP1425029A1 (en) | 2004-06-09 |
US7189755B2 (en) | 2007-03-13 |
WO2003013571A1 (en) | 2003-02-20 |
US20040167201A1 (en) | 2004-08-26 |
JP2005504043A (ja) | 2005-02-10 |
CA2462200A1 (en) | 2003-02-20 |
US20040152134A1 (en) | 2004-08-05 |
US20070155670A1 (en) | 2007-07-05 |
US7601753B2 (en) | 2009-10-13 |
EP1425029A4 (en) | 2006-06-07 |
US7326707B2 (en) | 2008-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002331064B2 (en) | Peptidomimetics of biologically active metallopeptides | |
AU2002331064A1 (en) | Peptidomimetics of biologically active metallopeptides | |
CN100384819C (zh) | 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂 | |
AU2002322466B2 (en) | Linear and cyclic melanocortin receptor-specific peptides | |
Williams et al. | 1-(((7, 7-Dimethyl-2 (S)-(2 (S)-amino-4-(methylsulfonyl) butyramido) bicyclo [2.2. 1] heptan-1 (S)-yl) methyl) sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor | |
US7964601B2 (en) | Melanocortin receptor-specific compounds | |
Sun et al. | Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics | |
Cai et al. | Biological and conformational study of β‐substituted prolines in MT‐II template: steric effects leading to human MC5 receptor selectivity | |
US7354923B2 (en) | Piperazine melanocortin-specific compounds | |
Creighton et al. | Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis | |
US7307063B2 (en) | Melanocortin metallopeptides for treatment of sexual dysfunction | |
US7385025B2 (en) | Metallopeptide compounds | |
Bourguet et al. | Benzophenone semicarbazone protection strategy for synthesis of aza‐glycine containing aza‐peptides | |
Lee et al. | Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at μ and δ opioid receptors | |
Mollica et al. | Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers | |
Hiebl et al. | Large‐scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling | |
Shreder et al. | Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics | |
Tian et al. | Discovery of orally bioavailable 1, 3, 4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents | |
Chang et al. | The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists | |
US6495358B1 (en) | Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes | |
Fry et al. | Utilizing peptide structures as keys for unlocking challenging targets | |
WO2005102340A1 (en) | Piperazine melanocortin-specific compounds | |
Biitseva et al. | 1H‐Isoindole‐Based Potential Peptidomimetics | |
ZA200509683B (en) | Melanocortin receptor-specific compounds | |
Hameed et al. | Recent Advances in the Design and Synthesis of Cyclic Peptidomimetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |